Renalytix Plc (RNLXY)
OTCMKTS · Delayed Price · Currency is USD
0.260
+0.015 (6.12%)
Jan 14, 2025, 4:00 PM EST

Renalytix Company Description

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States.

The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.

Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.

It has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model to improve kidney health and reduce kidney disease progression and kidney failure.

The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021.

The company was incorporated in 2018 and is based in New York, New York.

Renalytix Plc
Country United Kingdom
Founded 2018
Industry Health Information Services
Sector Healthcare
Employees 102
CEO James McCullough

Contact Details

Address:
1460 Broadway
New York, 10036
United States
Phone 646 397 3970
Website renalytix.com

Stock Details

Ticker Symbol RNLXY
Exchange OTCMKTS
Fiscal Year July - June
Reporting Currency USD
SIC Code 7372

Key Executives

Name Position
James R. McCullough M.B.A. Chief Executive Officer and Director
Fergus Fleming Chief Technology Officer and Executive Director
Dr. Michael J. Donovan M.D., Ph.D. Chief Medical Officer
Julian Huw Baines M.B.E. Executive Chairman
Howard B. Doran Jr. President
Joel R. Jung MBA Chief Financial Officer
Salim Gulamabbas Hamir F.C.A. Company Secretary